V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Supernus Pharmaceuticals Executive Compensation (FY25)

SUPN · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 18, 2026
300 figures on this page: 290 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Latest say-on-pay support
=
June 18, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jack Khattar: $12,640,989 → $15,501,557 (22.6% higher)
Say-on-pay support: 96.4% → 96.5% (0.1 points higher)

Frequently asked questions

Answers drawn from the data on this page.
What was Supernus Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 96.5% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in Supernus Pharmaceuticals' peer group?
The disclosed peer group names ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Amphastar Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc. and Axsome Therapeutics, Inc., among others.
What is Supernus Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 81:1 for fiscal 2025, against median employee compensation of $192,397.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack Khattar
Chief Executive Officer, President & Secretary
◇—◇◇◇—◇◇
Timothy Dec
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇— not reconciled
Frank Mottola
Senior Vice President, Chief Technical Operations Officer
◇—◇◇◇—◇◇
Jonathan Rubin
Senior Vice President, Chief Medical Officer Research and Development
◇—◇◇◇—◇◇
Padmanabh Bhatt
Senior Vice President, Intellectual Property, Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack Khattar
Chief Executive Officer, President & Secretary
◇—◇◇◇—◇◇
Timothy Dec
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Jonathan Rubin
Senior Vice President, Chief Medical Officer Research and Development
◇—◇◇◇—◇◇
Frank Mottola
Senior Vice President, Chief Technical Operations Officer
◇—◇◇◇—◇◇
Padmanabh Bhatt
Senior Vice President, Intellectual Property, Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack Khattar
Chief Executive Officer, President & Secretary
◇—◇◇◇—◇◇
Timothy Dec
Senior Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Jonathan Rubin
Senior Vice President, Chief Medical Officer, Research and Development
◇—◇◇◇—◇◇
Padmanabh Bhatt
Senior Vice President of Intellectual Property, Chief Scientific Officer
◇—◇◇◇—◇◇
Frank Mottola
Senior Vice President, Chief Technical Operations Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Frank MottolaOPTION◇——◇—◇◇
Frank MottolaOPTION◇——◇—◇◇
Frank MottolaOPTION◇——◇—◇◇
Jack A. KhattarOPTION◇——◇—◇◇
Jack A. KhattarOPTION◇——◇—◇◇
Jonathan RubinOPTION◇——◇—◇◇
Jonathan RubinOPTION◇——◇—◇◇
Jonathan RubinOPTION◇——◇—◇◇
Padmanabh P. BhattOPTION◇——◇—◇◇
Padmanabh P. BhattOPTION◇——◇—◇◇
Padmanabh P. BhattOPTION◇——◇—◇◇
Timothy C. DecOPTION◇——◇—◇◇
Timothy C. DecOPTION◇——◇—◇◇
Timothy C. DecOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jack KhattarPSU◇◇——
PSU◇◇——
Option◇—◇2/22/2034
Option◇—◇2/20/2035
Option◇—◇2/22/2032
Option◇—◇2/23/2033
Timothy DecRSU◇◇——
PSU◇◇——
Option◇—◇2/22/2032
Option◇—◇2/22/2034
RSU◇◇——
Option◇—◇2/23/2033
RSU◇◇——
Option◇—◇2/19/2035
Option◇—◇2/23/2033
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/22/2034
PSU◇◇——
Option◇—◇2/19/2035
Frank MottolaRSU◇◇——
PSU◇◇——
Option◇—◇2/22/2032
Option◇—◇2/22/2034
PSU◇◇——
RSU◇◇——
Option◇—◇2/23/2033
Option◇—◇2/19/2035
Padmanabh BhattOption◇—◇2/23/2033
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/19/2035
Option◇—◇2/22/2032
PSU◇◇——
RSU◇◇——
Option◇—◇2/22/2034
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Charles W. Newhall, III
Board chair
◇◇◇———◇
Georges Gemayel
◇◇◇———◇
Frederick M. Hudson
◇◇◇———◇
Carrolee Barlow
◇◇◇———◇
Bethany L. Sensenig
◇◇◇———◇
Jack A. Khattar served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Options (50/50 split).

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Amicus Therapeutics, Inc. FOLD
  • Amphastar Pharmaceuticals, Inc. AMPH
  • ANI Pharmaceuticals, Inc. ANIP
  • Axsome Therapeutics, Inc. AXSM
  • Catalyst Pharmaceuticals, Inc. CPRX
  • Collegium Pharmaceutical, Inc. COLL
  • Corcept Therapeutics Incorporated CORT
  • Dynavax Technologies Corporation DVAX
  • Harmony Biosciences Holdings, Inc. HRMY
  • Ligand Pharmaceuticals Incorporated LGND
  • Pacira Biosciences, Inc. PCRX
  • PTC Therapeutics, Inc. PTCT
  • Ultragenyx Pharmaceutical Inc. RARE
  • Xeris Biopharma Holdings, Inc. XERS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 18, 2026=◇◇◇
2024June 16, 2025=◇◇◇
2023June 14, 2024=◇◇◇
2022June 16, 2023=◇◇◇
2021June 17, 2022=◇◇◇
2020June 15, 2021=◇◇◇
2019June 15, 2020=◇◇◇
2018June 11, 2019=◇◇◇
2017June 12, 2018=◇◇◇
2016June 13, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Supernus Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Supernus Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Supernus Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Supernus Pharmaceuticals' disclosed peer group is defensible, who names Supernus Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
300 figures on this page: 290 cited to the filing that reported them, 10 calculated from figures it prints.
290 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001356576-26-000028
  2. 0001104659-26-053111
    CEO Pay Ratio · DIRECTOR COMPENSATION · Director Compensation · ELECTION OF DIRECTORS · and 4 more sections
  3. 0001356576-25-000042
  4. 0001104659-25-042531
    Summary Compensation Table
  5. 0001104659-24-072272
  6. 0001104659-24-054023
    Summary Compensation Table
  7. 0001104659-23-072558
  8. 0001104659-22-072424
  9. 0001356576-21-000058
  10. 0001356576-20-000041
  11. 0001356576-19-000010
  12. 0001104659-18-039860
  13. 0001104659-17-038942
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Supernus Pharmaceuticals executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/SUPN (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Supernus Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Supernus Pharmaceuticals discloses

The companies named in SUPN's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Amicus Therapeutics, Inc.Amphastar Pharmaceuticals, Inc.PTC Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.Xeris Biopharma Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy